Increasing incidence of sexually transmitted disease to augment the growth of the Peyronie's disease treatment market

 

Peyronie's disease (Pdy) is a sexually transmitted disease caused by the infectious agent of the same name - the bacteria known as folliculitis. Peyronie's disease is more common in men than in women, with approximately 3% of men being affected by it. This disease is most commonly associated with poor oral hygiene, although sexual intercourse can also cause it. The precise causes of this condition are not known, but heredity, diabetes, and injury to the urethra may all be contributing factors. The primary treatment of Peyronies is the surgical removal of the papillae, which are found on the tip of the penis. Peyronie's disease (Pdy) is clinically classified as an intervertebral disk disease and is often difficult to diagnose.

The growing prevalence of Peyronie’s disease around the globe is propelling the growth of the Peyronie’s disease treatment market. According to the American Academy of Family Physicians, it primarily affects men between 45 and 60 years of age, although an age range of 18 to 80 years. This disease occurs more often in men between 40 to 70 years older. Improved healthcare facilities across developing regions coupled with the availability of the multiple treatment options due to advancement in technology are again propelling the market growth. Moreover, the increasing geriatric population around the globe is further projected to foster the growth of Peyronie’s disease treatment market.

From the geographical point of view, North America is projected to gain significant growth over the forecast period and this is attributed to the increasing spending on healthcare by the government in the region. According to the U.S. Centers for Medicare & Medicaid Services, the U.S. health care spending grew 4.6 percent in 2019, reaching $3.8 trillion or $11,582 per person.  As a share of the nation's Gross Domestic Product, health spending accounted for 17.7 percent.

Key Developments:

1.      In April 2018, Paladin Labs Inc., a subsidiary of Endo International plc. announced the launch of a new indication for XIAFLEX® (collagenase clostridium histolyticum), the first and only Health Canada-approved treatment for appropriate patients with Peyronie's Disease. XIAFLEX®, distributed and promoted by Paladin Labs, in Canada.

2.      In October 2019, Endo International plc. announced that five new studies of XIAFLEX® (collagenase clostridium histolyticum) for the treatment of Peyronie's disease have presented as poster presentations at the 20th Annual Fall Meeting of the Sexual Medicine Society of North America (SMSNA) in Nashville.